Based on the increased lysosome proteolytic activity following genetic and pharmacological inhibition of LRRK2, we predicted that the gain-of-function LRRK2 G2019S Parkinson’s disease mutant which has increased kinase activity would have the opposite effect. This evidence concerns the gene LRRK2 and Parkinson disease.